Oxtoby Andrew 4

What Happened
Andrew Oxtoby, President and Chief Executive Officer of Kalaris Therapeutics, was granted a derivative award — an option covering 222,000 shares — on March 19, 2026. The grant shows an exercise/acquisition price of $0.00 on the Form 4 (i.e., the instrument reported is a compensatory option/award rather than an open-market purchase or sale).

Key Details

• Transaction date: March 19, 2026. Filing date (Form 4): March 20, 2026 (appears timely; Form 4s are generally due within two business days).
• Transaction type/code: A = Award/Grant of a derivative security (option).
• Shares/options: 222,000 underlying shares granted; reported $0.00 as the price on the filing (reflects an option grant, not an immediate cash transaction).
• Vesting/footnote: Footnote F1 — the option vests over four years: 25% vest on March 19, 2027, with the remainder vesting in equal monthly installments thereafter, subject to continuous service.
• Shares owned after transaction: Not specified in the information provided in this summary.

Context
This filing reports an option grant (a compensatory award) rather than a purchase or sale. Option grants are typically part of executive compensation and do not represent an immediate cash investment by the insider. The shares are subject to a multi-year vesting schedule, meaning the insider only gains the right to those shares over time and contingent on continued service.